<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    1973768
   </pmid>
   <datecreated>
    <year>
     1990
    </year>
    <month>
     08
    </month>
    <day>
     27
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1990
    </year>
    <month>
     08
    </month>
    <day>
     27
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0140-6736
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       336
      </volume>
      <issue>
       8709
      </issue>
      <pubdate>
       <year>
        1990
       </year>
       <month>
        Jul
       </month>
       <day>
        28
       </day>
      </pubdate>
     </journalissue>
     <title>
      Lancet
     </title>
     <isoabbreviation>
      Lancet
     </isoabbreviation>
    </journal>
    <articletitle>
     Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre.
    </articletitle>
    <pagination>
     <medlinepgn>
      193-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      The efficacy of treatment with TSH-suppressive doses of L-thyroxine (T4, 2.5 micrograms/kg body weight daily) either alone or combined with carbimazole (CBZ, 40 mg daily) was studied in 78 patients with sporadic non-toxic goitre in a prospective placebo-controlled double-blind randomised clinical trial. Treatment was given for 9 months, with 9 months of follow-up. A response to treatment as measured by ultrasonography was found in 58% of the T4 group, in 35% of the T4/CBZ group, and in 5% of the placebo group. The mean (SEM) decrease of thyroid volume at 9 months in the responders was 25% (2). After discontinuation of treatment, thyroid volume increased in the responders and had returned to base-line values after 9 months of follow-up. In the placebo group mean thyroid volume had increased by 6% (4) at 4 months, 20% (7) at 9 months, and 27% (8) at 18 months. The findings show that untreated sporadic non-toxic goitre continues to increase in size; T4 is effective in the treatment of the disorder; and the addition of CBZ has no therapeutic advantage.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine, University of Amsterdam, The Netherlands.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Berghout
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wiersinga
      </lastname>
      <forename>
       W M
      </forename>
      <initials>
       WM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Drexhage
      </lastname>
      <forename>
       H A
      </forename>
      <initials>
       HA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Smits
      </lastname>
      <forename>
       N J
      </forename>
      <initials>
       NJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Touber
      </lastname>
      <forename>
       J L
      </forename>
      <initials>
       JL
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Lancet
    </medlineta>
    <nlmuniqueid>
     2985213R
    </nlmuniqueid>
    <issnlinking>
     0140-6736
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Placebos
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      22232-54-8
     </registrynumber>
     <nameofsubstance>
      Carbimazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      6893-02-3
     </registrynumber>
     <nameofsubstance>
      Triiodothyronine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      7488-70-2
     </registrynumber>
     <nameofsubstance>
      Thyroxine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9002-71-5
     </registrynumber>
     <nameofsubstance>
      Thyrotropin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Carbimazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Goiter
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Placebos
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Recurrence
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thyrotropin
     </descriptorname>
     <qualifiername majortopicyn="N">
      antagonists &amp; inhibitors
     </qualifiername>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thyroxine
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Triiodothyronine
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1990
     </year>
     <month>
      7
     </month>
     <day>
      28
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1990
     </year>
     <month>
      7
     </month>
     <day>
      28
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1990
     </year>
     <month>
      7
     </month>
     <day>
      28
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     1973768
    </articleid>
    <articleid idtype="pii">
     0140-6736(90)91730-X
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

